Recent Searches
Life Sciences
As costs escalate, demographics shift and regulatory complexities increase, life sciences companies can’t hold on to the past — new approaches are needed to deliver personalized care and better health outcomes faster and with greater efficiency.
34,500+
life sciences practitioners worldwide are ready to help clients today.
8,400+
global life sciences clients trust EY to help them demonstrate greater value.
US$1b+
annual investment in data, tech and AI to solve complex client challenges.
Solving your complex challenges
- Capital allocation
- Operational efficiency
- Digital manufacturing
- Launch optimization
CHALLENGE
Allocate capital effectively to generate growth, improve returns and achieve long-term objectives.
Companies need acquisitions and alliances to build their portfolios. With heavy competition for assets across a widening frontier of innovation, companies need to partner more effectively across a wider range of both technologies and geographies.
HOW EY CAN HELP
EY helps life sciences’ clients partner across the innovation ecosystem to accelerate growth, enhance agility, reduce time-to-market and scale impactful innovations.
- Value creation: Helping clients refine their growth strategy, perform deal sourcing, conduct diligence and valuation, and implement M&A integration.
- Deep insight into portfolio management: Facilitating strategic portfolio management and better divestments that help clients improve value from the sale of an entire company, carve-out, spin-off or joint venture.
- Financial performance transformation: Supporting clients with their business challenges from every angle and helping them rapidly create, preserve and recover value.
FEATURED
EY Firepower report: life sciences dealmaking – trends in 2026
Dealmaking will continue to be driven not by market variations but by strategic fundamentals.
CHALLENGE
Improve operational efficiency by taking costs out to fund growth
Reducing costs and optimizing operations remains a top priority, across back-office functions from Global Business Services (GBS) to risk, regulatory and other processes. Agentic AI has emerged as a key lever for streamlining operations and protecting margins.
HOW EY CAN HELP
EY supports life sciences clients in achieving operational efficiency by helping them to optimize end-to-end value chain to control costs, ensure product/service quality and adherence to regulations, and fund innovation.
- Redesign operating models for agility: Helping clients rethink internal and external processes to drive speed, resilience and customer-centricity.
- Implement digital performance frameworks: Offering real-time data monitoring, cloud solutions and process integration to enhance manufacturing reliability and productivity. A digital-first approach supports cross-functional collaboration and long-term operational resiliency.
- Drive holistic transformation for sustainable success: Creating siloed operations and legacy systems with integrated strategies that align with evolving stakeholder expectations and regulatory demands.
- Enable talent for operational agility: Equipping teams with the right tools, training and upskilling programs to foster a culture of continuous improvement.
FEATURED
How life sciences legal teams prepare for a technology-driven future
Advances in healthcare technology create new data flows for life sciences companies, shifting the landscape for legal departments.
CHALLENGE
Configure adaptive manufacturing and supply chains
The industry’s manufacturing model faces onshoring pressures, soaring logistical costs, supply vulnerabilities and counterfeiting challenges. Companies need a smarter, AI-assisted digital manufacturing model that can ensure supply chain security, visibility, agility and operational resilience.
HOW EY CAN HELP
EY helps life sciences clients improve supply and demand synchronization via advanced analytics and the creation of new adaptive manufacturing capability.
- Smart manufacturing for resilient operations: Supporting clients in digitizing and automating core processes to improve quality, reducing costs and accelerating time-to-market.
- Predictive demand forecasting: Leveraging AI and advanced analytics to synchronize supply and demand, optimize inventory and improve production planning.
- AI-powered production transformation: Applying agentic AI, virtual twin technology and predictive analytics to optimize batch review, yield and quality control.
- Collaborative digital ecosystems: Building agile, cross-functional ecosystems that connect teams, data and systems across the value chain.
- Regulatory-ready automation: Deploying automation and digital tools that streamline compliance and reduce risk.
CHALLENGE
Use data more effectively to deliver innovation to patients faster
With development delays, failing launches and payer pushback, companies must bring commercial excellence into the end-to-end product lifecycle: accelerating from research and development to commercialization, leveraging next-generation Customer Relationship Management (CRM), and measuring real-world outcomes to support reimbursement.
HOW EY CAN HELP
EY helps life sciences implement new technologies and AI-powered solutions that enable holistic, high-quality care, products, services, and support digitized service models and operations.
- Accelerated launch strategies for market impact: Empowering biopharma teams to plan, execute and measure product launches with precision. Integrated strategy, operations and technology deliver faster, simpler and more successful launches.
- Behavioral benchmarking for salesforce excellence: Using data-led insights to optimize field-force performance, proven commercial behaviors are embedded in leaders and frontline teams to improve engagement and outcomes.
- Integrated CRM and regulatory platforms: Modernizing CRM and streamlining regulatory processes through unified platform adoption.
- Product Life Cycle and Portfolio management: Supporting clients in managing product portfolios and lifecycle strategies to improve commercial potential and align with evolving therapeutic priorities.
FEATURED
How biopharma can get the right mix of people and tech for launch success
Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed.
Explore our offerings
-
The EY Promotional Content Management Services team can provide you with support that will transform your processes and improve your results. Learn more.
Read more -
The EY Health Outcomes Platform aligns all stakeholders by providing a practical solution to operate value-based contracts at scale. Find out how.
Read more -
The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more -
Our Field-force Behavioral Benchmarking team can help your business achieve improved commercial performance. Find out how.
Read more -
Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more -
Our Healthcare Strategy Consulting teams help organizations develop digital, transaction and value strategies to build resilience and drive future growth
Read more
EY-Parthenon: Transformative strategy and transactions – solutions that work in practice, not just on paper.
Our latest thinking
2025 Global IPO market key highlights and 2026 outlook
The EY Global IPO Trends covers news and insights on the global IPO market for 2025 and an outlook for 2026. Learn more.
EY Pulse of the MedTech Industry Report 2026
The 20th edition of the EY Pulse of the MedTech Industry captures the medical devices sector at both a high point and a turning point. Find out how.
How next-generation CRM will reshape the life sciences commercial model
CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights—transform your customer engagement now. Read more.
EY Biotech Beyond Borders Report 2026
Biotech companies and life sciences leaders are seeking a balanced path forward between major opportunities and significant challenges. Find out how.
How biopharma can get the right mix of people and tech for launch success
Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed. Read more.
The Unstoppables: Success stories of the world’s most inspiring entrepreneurs
The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.
Why licensing deals are a powerful source of growth in life sciences
Innovation is key in Life Sciences. In response to challenges, pharmaceutical companies increasingly turn to external innovation, leveraging licensing deals. Learn more.
How life sciences can make the right deals in a time of change
Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.
How will you respond to clinicians sounding the alarm on unsustainable care delivery models?
The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.
Why digital supply chain visibility should be a pharma priority
With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.
How digital is changing the tax strategy for MedTech
As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.
How Takeda accelerated the financial close process by nearly two weeks
In this case study, learn how leading pharmaceutical company Takeda is creating value for patients through finance innovation and process excellence.
How early diagnosis can transform health care
Mirxes’ Dr. Zhou Lihan shares his purpose and passion for a more proactive approach to medicine. Learn more.
How innovation can unlock the power of data to deliver value-based care
Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Learn more.
How life sciences businesses transform the tax and finance function
Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.
Why life sciences tax departments need to act now on sustainability
Life sciences organizations should consider tax liabilities and compliance obligations resulting from myriad new sustainability taxes. Learn more.
How do you build future supply chains to best serve patient needs?
In the wake of global disruptions, EY research aims to map out the future for supply chain transformation in the pharmaceutical industry. Read more.
How CDMOs are leading innovation for pharmaceutical partners
Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.
What going digital means for Takeda
Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.
How to navigate global transfer pricing controversy in life sciences
Life sciences companies face growing tax authority scrutiny of their transfer pricing practices and must prepare for escalating controversy.
How you can create value in an intelligent health ecosystem
The intelligent health ecosystem will provide smarter insights and personalized health care experiences to patients, anytime and anywhere.
How to navigate EU regulations for drug-device combination products
The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.
How one entrepreneur seeks to make affordable health care a reality
Celltrion’s JungJin SEO shares his purpose and passion for more accessible health care. Learn more.
How ecosystem participation drives more value for life sciences deals
Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.
How to account for outcome-based payment arrangements in life sciences
The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.
How the future of health care is becoming a reality
Human-centric care will soon become a reality, driven by data and technology.
Five trends redefining the health sciences and wellness operating model
As demand from consumers accelerates the adoption of new technologies, we explore how companies can provide a more convenient health experience.
EY Partner Ecosystem
EY harnesses a connected ecosystem of strategic alliances and partnerships to co-create value and deliver comprehensive technology solutions and business outcomes for our clients.
Our latest thinking
How next-generation CRM will reshape the life sciences commercial model
CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights—transform your customer engagement now. Read more.
How Sigma, an Australian pharmaceutical company, transformed its supply chain
Discover how EY teams helped Sigma simplify and standardize to boost availability and cut inventory by 20%.
How Medtronic’s optimized supply chain gets products to patients in need
A global technology Life Sciences leader improved their supply chain planning to better serve patients. Learn more in this case study.
How IntraBio's finance transformation fueled its global expansion
For its global expansion, IntraBio needed to solve operational and financial back-office challenges. Learn how EY finance transformation services helped.
How biopharma can get the right mix of people and tech for launch success
Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed. Read more.
EY Firepower report: life sciences dealmaking – trends in 2026
Learn how life sciences organizations can accelerate dealmaking strategies to succeed.
Why licensing deals are a powerful source of growth in life sciences
Innovation is key in Life Sciences. In response to challenges, pharmaceutical companies increasingly turn to external innovation, leveraging licensing deals. Learn more.
How Bayer is unearthing agronomy's future with generative AI
Read this case study to learn how Bayer Crop Science is using large language models to plant the seeds of the future.
The team
Explore related sector pages: Consumer Products | Health | Retail